Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Oncopeptalks on the recent FDA decision

February 27, 2024 – In this episode of Oncopeptalks, Jakob Lindberg, Chief Scientific Officer discusses the recent decision by the U.S. Food and Drug Administration to reconfirm the withdrawal of Pepaxto in a conversation with David Augustsson, Head of IR and Communication.

See the FDA episode

CEO Sofia Heigis - Oncopeptides AB

Released February 27, 2024

Oncopeptides publishes year-end report 2023

Read report

Download

“The fourth quarter sets the stage for revenue acceleration in 2024”

CEO Sofia Heigis

 

See the Webcast

Webcast presentation as pdf

 

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Q1 interim report 2024 will be published May 3, 2024

Company news

Oncopeptides receives decision from the U.S. Food and Drug Administration confirming withdrawal of Pepaxto from the U.S. market

February 23, 2024 – Oncopeptides AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has made a decision regarding the withdrawal of Pepaxto, which Oncopeptides had appealed.

Read more

Oncopeptides receives positive recommendation for Pepaxti by Spanish Pricing Authority

February 23, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the Spanish Drug Pricing Authority (CIPM) has published a positive recommendation for the pricing of melflufen, branded in Europe as Pepaxti.

Read more

Oncopeptides ensures five years extended market exclusivity for Pepaxti in Europe

February 15, 2024 – Oncopeptides AB today announces that it will receive an extension of a key patent ensuring market exclusivity for melflufen, marketed in Europe as Pepaxti, in Europe until 2037, an extension of five years.

Read more

Science news

Type IB variation process finalized – original indication remains with peripheral administration included

February 7, 2024 - Oncopeptides recently received a favorable opinion from the European Medicines Agency (EMA) to revert back to the originally approved indication for Pepaxti. This means that the previously communicated decision to opt out of the process to extend the indication has now been fully realized.

Read more

Article with exploratory alkylator-refractory subgroup analysis from Oncopeptides’ OCEAN study observing longer PFS and OS in melflufen vs. pomalidomide published in European Journal of Haematology

November 17, 2023 - The results further demonstrate efficacy and consistent safety profile in patients with alkylator-refractory disease.

Read more

Oncopeptides selected to present additional data from OCEAN study at the American Society of Hematology meeting

November 13, 2023. Long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at ASH in San Diego, December 9-12.

Read more

Investor news

Oncopeptalks on the recent FDA decision

Read more

Invitation to presentation of the year-end report 2023

February 21, 2024 – Oncopeptides AB (publ) will publish the report for the fourth quarter and the 2023 year-end report on February 27, 2024. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session at 09:00 CET on the same day.

Read more

Oncopeptalks on the treatment landscape and competition

January 29, 2024 - Join David and Sofia for the first Oncopeptalks of the year – where Sofia deep dives into the rapidly changing treatment landscape for multiple myeloma and where Pepaxti is positioned versus its competitors.

Read more

Upcoming events

2024-04-03 - 2024-05-02

Silent Period

Other

2024-04-22

Annual report 2023

Report

2024-05-03

Interim Report Q1 2024

Report

Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Oncopeptides via e-mail